| abstract |
The invention concerns oligodeoxyribonucleotides, in which, at both the 5' and the 3' terminal positions, at least two 2'-deoxy-β-D-erythro-pentofuranosyl groups have been replaced by 2'-deoxy-β-D-threo-pentofuranosyl groups, and oligodeoxyribonucleotides in which at least 20 % of the 2'-deoxy-β-D-erythro-pentofuranosyl groups in successive nucleotide units have been replaced by 2'-deoxy-β-D-threo-pentofuranosyl groups, and which consist of 6 to 100 nucleotide units. Such oligodeoxyribonucleotides are suitable for use as anti-sense inhibitors of the expression of viral genes and oncogenes and can be used in the preparation of drugs with an anti-viral action. |